Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

18.28USD
17 Aug 2018
Change (% chg)

$0.02 (+0.11%)
Prev Close
$18.26
Open
$18.22
Day's High
$18.43
Day's Low
$18.01
Volume
252,762
Avg. Vol
402,748
52-wk High
$21.19
52-wk Low
$13.00

Latest Key Developments (Source: Significant Developments)

Ironwood Announces Management Changes Related To Separation Of Soluble Guanylate Cyclase Business From Commercial, Gastrointestinal Business
Tuesday, 12 Jun 2018 04:37pm EDT 

June 12 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD - ANNOUNCED MANAGEMENT CHANGES RELATED TO SEPARATION OF SOLUBLE GUANYLATE CYCLASE BUSINESS FROM COMMERCIAL, GASTROINTESTINAL BUSINESS.IRONWOOD SAYS WILL SEPARATE SOLUBLE GUANYLATE CYCLASE BUSINESS INTO 2 PUBLICLY TRADED COMPANIES 'RESEARCH AND DEVELOPMENT CO' AND 'NEW IRONWOOD' - SEC FILING.IRONWOOD PHARMACEUTICALS - EFFECTIVE UPON SEPARATION WILLIAM HUYETT TO BECOME CFO OF RESEARCH AND DEVELOPMENT CO.IRONWOOD PHARMACEUTICALS - GINA CONSYLMAN TO CONTINUE AS CFO OF NEW IRONWOOD.  Full Article

Nicox Announces Research Collaboration With Ironwood Pharmaceuticals
Wednesday, 6 Jun 2018 01:30am EDT 

June 6 (Reuters) - NICOX SA ::REG-NICOX ANNOUNCES RESEARCH COLLABORATION ON NOVEL OPHTHALMIC THERAPEUTICS WITH IRONWOOD PHARMACEUTICALS.EACH COMPANY WILL BE RESPONSIBLE FOR THEIR OWN COSTS ASSOCIATED WITH ACTIVITIES CARRIED OUT AS PART OF COLLABORATION.DEPENDING ON OUTCOME, COS MAY ENTER INTO DISCUSSIONS ON NICOX'S FURTHER DEVELOPMENT OF ANY IDENTIFIED PRODUCT CANDIDATE..  Full Article

Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08
Thursday, 15 Feb 2018 08:01am EST 

Feb 15 (Reuters) - Ironwood Pharmaceuticals Inc ::Q4 REVENUE $94.2 MILLION.‍EXPECT TO GENERATE POSITIVE CASH FLOW IN 4Q 2018​.QTRLY TOTAL REVENUES $94.2 MILLION VERSUS $87.5 MILLION.QTRLY GAAP NET INCOME PER SHARE BASIC AND DILUTED $0.08 ‍​.Q4 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 ‍​.  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 08:38am EST 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 08:30am EST 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 11:51am EST 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Ironwood Pharmaceuticals Strengthens Executive Leadership Team
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.IRONWOOD PHARMACEUTICALS INC - PROMOTED ‍ GINA CONSYLMAN TO SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.  Full Article

Ironwood Pharma files for potential mixed shelf offering
Thursday, 2 Nov 2017 05:36pm EDT 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18
Thursday, 2 Nov 2017 08:01am EDT 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Q3 non-GAAP loss per share $0.18.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals provides third quarter 2017 investor update.Q3 loss per share $0.22.Q3 revenue $87 million versus I/B/E/S view $73.6 million.Ironwood Pharmaceuticals Inc sees 2017 ‍R&D expenses to be in low-to-middle end of previously guided $145 million to $160 million range​.Ironwood Pharmaceuticals Inc - ‍data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017​.Ironwood Pharmaceuticals Inc - ‍to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided​.Ironwood - sees co & Allergan's ‍combined total 2017 marketing & sales expenses for Linzess in middle of previously guided $250 million to $280 million range​.Ironwood Pharmaceuticals Inc - co & Allergan no longer intend to pursue linaclotide delayed release-1​.  Full Article

Ironwood Pharma says CFO Tom Graney will leave company
Wednesday, 6 Sep 2017 08:00am EDT 

Sept 6 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company.Ironwood Pharmaceuticals Inc - ‍gina Consylman will serve as company's interim chief financial officer​.Ironwood Pharmaceuticals Inc - ‍initiated search for a senior business strategy and finance executive to complement its current leadership team​.  Full Article

BRIEF-Ironwood Pharma Sends Letter To Shareholders Highlighting Director Nominees

* IRONWOOD PHARMACEUTICALS SENDS LETTER TO SHAREHOLDERS HIGHLIGHTING DIRECTOR NOMINEES